JPWO2020168079A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020168079A5 JPWO2020168079A5 JP2021547420A JP2021547420A JPWO2020168079A5 JP WO2020168079 A5 JPWO2020168079 A5 JP WO2020168079A5 JP 2021547420 A JP2021547420 A JP 2021547420A JP 2021547420 A JP2021547420 A JP 2021547420A JP WO2020168079 A5 JPWO2020168079 A5 JP WO2020168079A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- use according
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 72
- 239000000427 antigen Substances 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 61
- 238000005303 weighing Methods 0.000 claims description 45
- 206010028417 myasthenia gravis Diseases 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 238000012423 maintenance Methods 0.000 claims description 30
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 14
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 14
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 14
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims description 14
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 14
- 230000007423 decrease Effects 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 7
- 102000009109 Fc receptors Human genes 0.000 claims description 7
- 108010087819 Fc receptors Proteins 0.000 claims description 7
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 7
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 7
- 229960001230 asparagine Drugs 0.000 claims description 7
- 235000009582 asparagine Nutrition 0.000 claims description 7
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 101100440311 Homo sapiens C5 gene Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 230000003862 health status Effects 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229940124073 Complement inhibitor Drugs 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000004074 complement inhibitor Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051765A JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805350P | 2019-02-14 | 2019-02-14 | |
| US62/805,350 | 2019-02-14 | ||
| US201962814935P | 2019-03-07 | 2019-03-07 | |
| US62/814,935 | 2019-03-07 | ||
| PCT/US2020/018113 WO2020168079A1 (en) | 2019-02-14 | 2020-02-13 | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051765A Division JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520107A JP2022520107A (ja) | 2022-03-28 |
| JP2022520107A5 JP2022520107A5 (https=) | 2023-02-20 |
| JPWO2020168079A5 true JPWO2020168079A5 (https=) | 2023-02-20 |
Family
ID=69954108
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547420A Withdrawn JP2022520107A (ja) | 2019-02-14 | 2020-02-13 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
| JP2025051765A Pending JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051765A Pending JP2025092553A (ja) | 2019-02-14 | 2025-03-26 | 全身型重症筋無力症を治療するための抗ｃ５抗体の投与量及び投与 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200331993A1 (https=) |
| EP (1) | EP3924380A1 (https=) |
| JP (2) | JP2022520107A (https=) |
| KR (1) | KR20210126045A (https=) |
| CN (2) | CN119326881A (https=) |
| AU (1) | AU2020223298A1 (https=) |
| CA (1) | CA3130300A1 (https=) |
| MX (1) | MX2021009789A (https=) |
| WO (1) | WO2020168079A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| US20220059221A1 (en) * | 2020-08-24 | 2022-02-24 | Nvidia Corporation | Machine-learning techniques for oxygen therapy prediction using medical imaging data and clinical metadata |
| KR20230134533A (ko) * | 2021-01-22 | 2023-09-21 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5 항체를 이용한 보체 매개 혈전성 미세혈관병증의치료 방법 |
| JP2024526742A (ja) * | 2021-07-14 | 2024-07-19 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| JP2019517473A (ja) * | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| SI3658184T1 (sl) * | 2017-07-27 | 2024-01-31 | Alexion Pharmaceuticals, Inc., | Formulacije z visoko koncentracijo protiteles proti-C5 |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
-
2020
- 2020-02-13 MX MX2021009789A patent/MX2021009789A/es unknown
- 2020-02-13 CA CA3130300A patent/CA3130300A1/en active Pending
- 2020-02-13 EP EP20713785.2A patent/EP3924380A1/en active Pending
- 2020-02-13 CN CN202411307488.2A patent/CN119326881A/zh active Pending
- 2020-02-13 KR KR1020217028172A patent/KR20210126045A/ko not_active Ceased
- 2020-02-13 CN CN202080021230.XA patent/CN113614106A/zh active Pending
- 2020-02-13 JP JP2021547420A patent/JP2022520107A/ja not_active Withdrawn
- 2020-02-13 WO PCT/US2020/018113 patent/WO2020168079A1/en not_active Ceased
- 2020-02-13 AU AU2020223298A patent/AU2020223298A1/en active Pending
- 2020-02-14 US US16/791,415 patent/US20200331993A1/en not_active Abandoned
-
2024
- 2024-10-31 US US18/933,215 patent/US20250243264A1/en active Pending
-
2025
- 2025-03-26 JP JP2025051765A patent/JP2025092553A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113423426B (zh) | 使用抗FcRn抗体治疗格雷夫斯眼病的方法 | |
| JP7728374B2 (ja) | 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 | |
| JP2021526534A5 (https=) | ||
| JP2018535948A5 (https=) | ||
| RU2015114923A (ru) | СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| US20200239582A1 (en) | Methods For Treating Type 1 Diabetes Using Glucagon Receptor Antagonistic Antibodies | |
| JP2021525718A5 (https=) | ||
| CA3187866A1 (en) | Inflammatory cytokines and fatigue in subject with a complement mediated disease | |
| CN111886252A (zh) | 促进胰岛细胞生长的方法 | |
| US20120308564A1 (en) | Treatment of a metabolic disorder | |
| JPWO2020168079A5 (https=) | ||
| KR20120011883A (ko) | 다발성 경화증의 치료 | |
| TW202321303A (zh) | 抗pla2r自體抗體媒介膜性腎病變之治療 | |
| JPWO2019231983A5 (https=) | ||
| JPWO2020154626A5 (https=) | ||
| CA3209172A1 (en) | Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection | |
| CN116635422A (zh) | 抗cd38抗体及其用途 | |
| JPWO2022011086A5 (https=) | ||
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| RU2812670C2 (ru) | Агонистическое антитело к рецептору лептина для применения в лечении нарушения метаболизма или гиполептинемии | |
| CN118076640A (zh) | 抗-pla2r自身抗体介导的膜性肾病的治疗 | |
| WO2025085971A1 (en) | Anti-tau therapeutic antibody for ad and tauopathies | |
| CN116997570A (zh) | 用于治疗抗体介导的移植排斥的抗cd38抗体 | |
| TH2101002581A (th) | วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn | |
| JP2021518393A5 (https=) |